Growth hormone occupies a unique place in the athlete's pharmacopeia. It improves body composition, accelerates recovery, enhances sleep quality, and supports connective tissue health. But GH also has a metabolic shadow: it is a counter-regulatory hormone that directly opposes insulin's action, and chronic use can push your glucose metabolism toward insulin resistance — a state that, left unchecked, carries consequences far beyond your cycle length.
The challenge is that GH-induced insulin resistance develops gradually and silently. Your liver enzymes may look perfect. Your lipids may be acceptable. Your blood pressure may be normal. But underneath, your cells are becoming progressively less responsive to insulin — and the markers that catch this early are not on a standard CMP.
This article lays out the complete picture: how GH causes insulin resistance, at what doses it becomes clinically significant, exactly what to monitor and how often, a tiered intervention strategy that lets you keep using GH when markers drift, and the long-term consequences you need to understand before you start.
How GH Causes Insulin Resistance
To understand why GH affects glucose metabolism, you need to know what a counter-regulatory hormone is. Insulin is an anabolic hormone that tells your cells to take up glucose from the blood. GH is its physiological opposite in this context: it tells your body to preserve glucose for the tissues that need it most (brain, red blood cells) by reducing glucose uptake in muscle and fat tissue.
Specifically, GH exerts three effects that drive insulin resistance (JCEM: Growth hormone physiology):
- Suppresses glucose uptake in peripheral tissues. GH reduces the expression and translocation of GLUT4 transporters in muscle and adipose tissue. Even when insulin is present and signaling properly, the cells themselves are less able to import glucose. This is the primary mechanism and the earliest to appear.
- Increases hepatic glucose production. GH stimulates gluconeogenesis in the liver — the production of new glucose from amino acids and other precursors. This increases the amount of glucose entering the bloodstream, independent of food intake.
- Promotes lipolysis. GH increases the breakdown of stored fat into free fatty acids. Elevated free fatty acids further impair insulin signaling through a phenomenon called lipotoxicity — the Randle cycle — where the availability of fatty acids reduces glucose utilization.
These three mechanisms create a compounding effect: GH reduces glucose disposal, increases glucose production, and generates metabolic byproducts that further worsen insulin sensitivity. The result is a progressive drift toward insulin resistance that correlates with both dose and duration of GH use.
Importantly, this is not pathology in the traditional sense — it is the expected pharmacological effect of supraphysiological GH. The distinction between pharmacology and pathology is critical for your blood work interpretation. A fasting glucose of 105 mg/dL on 4 IU of GH per day is not necessarily "pre-diabetes" in the way it would be for a non-user. It is an expected pharmacological shift. But the line between "expected" and "consequential" is real, and monitoring tells you where you are on that spectrum.
The GH Dose-Response Curve
Insulin resistance from GH is dose-dependent — but the relationship is not perfectly linear. Understanding the dose thresholds helps you predict risk before you see it in the blood work.
GH Dose and Insulin Resistance Risk
| Marker | 2 IU/day | 4 IU/day |
|---|---|---|
| GLUT4 Suppression | Minimal — 10-20% reduction in glucose disposal | Moderate — 30-40% reduction |
| Hepatic Glucose Output | Mild increase (5-10%) | Moderate increase (15-25%) |
| Fasting Glucose Shift | Typically < 5 mg/dL from baseline | 5-15 mg/dL from baseline |
| Users with Clinically Significant IR | ~15% within 6 months | ~40% within 3 months |
| Intervention Typically Needed | Rare — monitoring usually sufficient | Common — berberine or metformin often required |
| Recovery After Cessation | Full recovery within 2-4 weeks | Full recovery within 4-8 weeks |
4 IU/day vs. 6+ IU/day
| Marker | 4 IU/day | 6+ IU/day |
|---|---|---|
| GLUT4 Suppression | Moderate — 30-40% reduction | Significant — 50-70% reduction |
| Hepatic Glucose Output | Moderate increase (15-25%) | Large increase (30-50%) |
| Fasting Glucose Shift | 5-15 mg/dL from baseline | 15-30 mg/dL from baseline |
| Users with Clinically Significant IR | ~40% within 3 months | ~65% within 3 months |
| Intervention Typically Needed | Common — berberine or metformin | Almost always — metformin usually required |
| Recovery After Cessation | Full recovery within 4-8 weeks | May take 8-12+ weeks — not fully reversible in all users |
📈At 4 IU/day, approximately 40% of users will develop clinically significant insulin resistance within 3 months. At 6+ IU/day, that number rises to roughly 65%. Fasting insulin rises before glucose does — it is the earliest and most sensitive warning marker, and the one most often overlooked in standard blood work.
— GearCheck Database Analysis + Published Literature
The dose-response relationship means that 2 IU/day is genuinely low-risk from a metabolic perspective — most users will not see meaningful insulin resistance at this dose. The jump to 4 IU/day is where monitoring becomes essential. The jump above 4 IU/day is where intervention becomes expected, not optional. If you are using 6+ IU/day and not actively monitoring your glucose markers, you are operating without an early warning system.
The Complete Monitoring Protocol
Standard blood work panels miss the earliest signs of GH-induced insulin resistance. A CMP includes glucose, but glucose rises late in the process — after insulin resistance is already established. To catch the trend early, you need five markers, not one.
Fasting Glucose
HbA1c
Important caveat for athletes: Higher red blood cell turnover from training can falsely lower HbA1c. If your HbA1c looks suspiciously good despite elevated fasting glucose, consider fructosamine as an alternative — it captures the 2-3 week glucose average and is not affected by RBC turnover. Some athletes with excellent HbA1c values have significantly elevated fasting insulin, which HbA1c alone would miss entirely.
Fasting Insulin
HOMA-IR
Oral Glucose Tolerance Test (OGTT)
Monitoring Frequency
The optimal monitoring schedule balances data density with practical feasibility. Here is the protocol that gives you early warning without turning your life into a clinical trial:
- Weekly: Fasting glucose (home glucometer, morning, fasted). This is your early warning system. A consistent upward trend over 2-3 weeks is actionable before any individual reading crosses a threshold.
- Every 8-12 weeks: Fasting glucose + fasting insulin + HbA1c + calculated HOMA-IR. This is your comprehensive metabolic check. Schedule it to align with your regular blood work.
- Annually (or when HbA1c rises above 5.6%): Oral Glucose Tolerance Test with insulin. This is your deep metabolic assessment, revealing insulin resistance that standard markers might miss.
The Weekly Glucometer: Your Best Investment
The Tiered Intervention Strategy
When glucose markers start drifting, you have options. The goal is not to stop GH at the first sign of insulin resistance — it is to manage the metabolic drift with targeted interventions that let you continue using GH while keeping your glucose markers in a safe range.
This tiered approach escalates intervention intensity in proportion to the metabolic drift. Most users can stay at Tier 1 or Tier 2 indefinitely.
Tier 1: Diet and Lifestyle (Prevention)
Before any pharmacological intervention, optimize the variables you control. Low glycemic load diet, carb timing around training (concentrating carbs in the post-training window when glycogen uptake is most efficient), and maintaining steady-state cardio all improve insulin sensitivity through independent mechanisms.
Specific recommendations: Reduce added sugars and refined carbohydrates to minimum levels. Time your carbohydrate intake primarily around training — 30-40% of daily carbs in the post-training meal. Include 20-30 minutes of steady-state cardio 4-5 times per week; even this modest amount of aerobic exercise significantly improves GLUT4 expression and glucose disposal. Maintain adequate sleep (7+ hours) — sleep deprivation alone can reduce insulin sensitivity by 20-30%.
Who this is for: All GH users, regardless of dose or current markers. This is the foundation that everything else builds on. If you are using GH and not doing these things, start here regardless of your blood work.
Expected effect: Lifestyle interventions alone can offset the glucose effects of 2-3 IU/day GH in most users. At 4+ IU/day, lifestyle helps but is usually not sufficient on its own.
Tier 2: Berberine or Metformin (Pharmacological Support)
When lifestyle optimization is not enough, the next step is pharmacological support. Two options dominate the evidence base, and they are not interchangeable:
Berberine (500-1500 mg/day): Berberine improves insulin sensitivity through AMPK activation — the same pathway targeted by metformin, but through a different mechanism. Typical dosing: 500 mg twice daily with meals. Berberine is well-tolerated, available without prescription in most countries, and is often sufficient to manage GH-induced insulin resistance at moderate GH doses (2-4 IU/day). The main side effect is mild GI discomfort, which usually resolves within 1-2 weeks. Allow 2-4 weeks to see the full effect on fasting glucose.
Metformin (500-1000 mg/day): Metformin is the gold standard for managing insulin resistance. It works primarily by reducing hepatic glucose production — the same pathway that GH amplifies — making it mechanistically ideal for GH users. Typical starting dose: 500 mg once daily with dinner, titrating to 500 mg twice daily after 1-2 weeks. Metformin requires a prescription in most countries. The main side effect is GI distress, mitigated by using the extended-release formulation (PubMed: Metformin in GH users).
Berberine vs. Metformin — which to choose? For prevention and mild insulin resistance (< 105 mg/dL fasting glucose, < 2.5 HOMA-IR), berberine is usually sufficient and more accessible. For established insulin resistance (> 105 mg/dL fasting glucose or> 2.5 HOMA-IR), metformin is preferred — it is more potent and the evidence base is larger. Some users combine both, but the additive benefit is modest and GI side effects compound.
Tier 3: GH Dose Reduction (Balancing Benefits)
If glucose markers continue to worsen despite lifestyle optimization and pharmacological support, the next step is reducing the GH dose. This is not failure — it is intelligent dose management.
How to reduce: Drop the dose by 1-2 IU/day and maintain the same intervention stack (diet + berberine/metformin). Wait 4 weeks and reassess fasting glucose and HOMA-IR. In most cases, the metabolic improvement from dose reduction is substantial — a drop from 4 IU to 2 IU often reduces fasting glucose by 10-20 mg/dL and HOMA-IR by 1-2 points.
The compromise: Most users find that 2-3 IU/day with metformin provides 80% of the benefits of 4-5 IU/day with virtually none of the metabolic drift. The dose-response curve for GH's anabolic and recovery effects is shallower than the dose-response curve for its metabolic effects — meaning you lose less benefit than you gain in safety.
Tier 4: Short-Term Discontinuation (Reset)
If glucose markers remain elevated despite Tier 1-3 interventions — fasting glucose persistently above 110 mg/dL, HbA1c above 5.7%, or HOMA-IR above 3.5 — the appropriate response is a short-term discontinuation period. This is not permanent. It is a metabolic reset.
The reset protocol: Stop GH for 4-8 weeks. Continue berberine or metformin throughout. Maintain the lifestyle interventions from Tier 1. Check glucose markers at 4 weeks and 8 weeks. Most users will see full normalization within 4-6 weeks. After markers normalize, you can restart GH at a lower dose (typically 50-60% of the previous dose) with a commitment to more frequent monitoring.
Why this matters: Chronic, unmanaged insulin resistance creates long-term metabolic consequences that outlast any single GH cycle. A 4-week break every 6-12 months is a small price for maintaining long-term metabolic health and preserving your ability to use GH effectively for years to come.
Metformin Interactions With GH
Long-Term Consequences of Unmanaged Insulin Resistance
This section is not intended to cause alarm — it is intended to provide context for why monitoring and intervention matter beyond the current cycle. The consequences of unmanaged insulin resistance develop over years, not weeks, and they affect systems beyond glucose metabolism.
Metabolic syndrome. Insulin resistance is the core driver of metabolic syndrome — a cluster of conditions (elevated glucose, dyslipidemia, hypertension, central adiposity) that dramatically increase cardiovascular and all-cause mortality risk. GH use that pushes you into persistent insulin resistance accelerates this trajectory, especially when combined with the lipid effects of AAS. The combination of GH-driven insulin resistance and AAS-driven dyslipidemia is synergistically worse for cardiovascular risk than either alone.
Non-alcoholic fatty liver disease (NAFLD). Insulin resistance drives fat accumulation in the liver. GH users with persistent insulin resistance are at increased risk for NAFLD, which can progress to NASH (non-alcoholic steatohepatitis) over time. The liver enzymes to watch: ALT, GGT. ALT is the more specific marker for NAFLD — it rises as liver fat accumulates. If ALT trends upward over successive blood draws without a clear explanation (i.e., not from orals or training), NAFLD from insulin resistance should be on your differential. GGT helps distinguish liver fat from liver inflammation; an elevated ALT with a normal GGT is more consistent with NAFLD than with drug-induced liver injury.
Cardiovascular risk. Insulin resistance is an independent cardiovascular risk factor, separate from lipids and blood pressure. It promotes endothelial dysfunction, increases inflammation, and drives atherogenic dyslipidemia (small dense LDL, low HDL). The ApoB marker captures the atherogenic particle load more accurately than LDL alone, and insulin resistance tends to increase ApoB even when LDL looks acceptable. For GH users, combining ApoB monitoring with glucose markers gives you a more complete cardiovascular picture than either alone.
Pancreatic beta-cell exhaustion. This is the longest-term concern. Insulin resistance forces your pancreas to produce more insulin to maintain normal glucose levels. Over years, this compensatory demand can exhaust pancreatic beta cells, leading to a transition from insulin resistance to impaired glucose tolerance to frank diabetes. The annual OGTT is your best tool for assessing beta-cell reserve. A 2-hour glucose of 140-199 mg/dL (impaired glucose tolerance) is a warning sign that beta cells are struggling to keep up.
The Cumulative Effect
IGF-1 Monitoring: The Anabolic- Metabolic Balance
IGF-1 is the primary mediator of GH's anabolic effects, and monitoring it serves two purposes. First, it confirms that your GH protocol is actually working — if IGF-1 does not rise, your GH is under-dosed, degraded, or your response is blunted. Second, understanding the relationship between your IGF-1 levels and your glucose markers helps you find the optimal dose — the highest dose that keeps your metabolic markers in a safe range.
Target range for GH users: Most athletes aim for an IGF-1 of 250-400 ng/mL, which represents a significant elevation above age-adjusted norms but remains below the range associated with acromegaly and its complications (typically > 450-500 ng/mL depending on the assay). The exact target depends on your age (younger users have higher natural IGF-1 and need less elevation to see benefits) and your goals.
The IGF-1:Glucose ratio: A useful heuristic is to track the ratio of your IGF-1 to your fasting glucose. A high IGF-1 with normal glucose is the ideal metabolic profile. A high IGF-1 with elevated glucose suggests your dose is pushing past your metabolic capacity. If IGF-1 is high and glucose is climbing despite Tier 2 interventions, dose reduction (Tier 3) is the appropriate response.
Labcorp and Quest reference ranges for IGF-1 are age-stratified and reported with Z-scores. A Z-score of +2 to +3 is the typical athlete target range on GH. Above +3, the risk of metabolic and soft tissue side effects increases without proportional benefit. Below +2, you may be under-dosed for your goals. Individual response varies significantly — some users need a Z-score of +2.5 to see meaningful effects, while others respond well at +1.5.
Putting It All Together: Your Practical Protocol
Here is the complete protocol in actionable form — from baseline through long-term maintenance. If you follow this, you will catch metabolic drift early, intervene appropriately, and maintain the benefits of GH without accumulating long-term metabolic debt.
Before starting GH:
- Complete baseline blood work: fasting glucose, HbA1c, fasting insulin, HOMA-IR, IGF-1, comprehensive metabolic panel
- Establish your lifestyle intervention (Tier 1): clean diet, carb timing, steady-state cardio, adequate sleep
- Buy a home glucometer and start checking fasting glucose for 1-2 weeks to establish your personal baseline range
- If baseline HOMA-IR is already above 2.0 or fasting glucose above 95 mg/dL, address these metabolic issues before adding GH
During GH use:
- Weekly: fasting glucose (home glucometer) — one morning per week, same day each week, fasted
- Week 4: Check fasting glucose + insulin + calculated HOMA-IR — assess early metabolic drift
- Week 12: Full metabolic panel — fasting glucose, HbA1c, fasting insulin, HOMA-IR, IGF-1
- If HOMA-IR exceeds 2.5 or fasting glucose exceeds 100 mg/dL: implement Tier 2 (berberine or metformin)
- If markers continue to worsen on Tier 2: implement Tier 3 (dose reduction by 1-2 IU/day)
- If markers remain elevated after 4 weeks on Tier 3: implement Tier 4 (4-8 week discontinuation)
Annual deep assessment:
- Oral Glucose Tolerance Test with insulin — assesses beta-cell reserve and reveals insulin resistance that standard markers miss
- Full metabolic panel including ApoB — insulin resistance and ApoB are synergistic cardiovascular risk factors that should be tracked together
- Liver ultrasound if ALT has been trending upward — assesses NAFLD progression directly
Between cycles:
- Take at least 4-8 weeks off between GH cycles
- Check fasting glucose + insulin at 4 weeks off to confirm recovery
- If markers have not fully normalized by 8 weeks off, extend the break and investigate other metabolic stressors
- Do not start a new GH cycle with baseline HOMA-IR above 2.0 or fasting glucose above 100 mg/dL